ATP synthase membrane subunit g pseudogene 3Genealiases: ATP5KP3 · ATP5LP3 · ATPE5KP3
Q-omics provides the consensus-scored ATP5MGP3 profile across patient tissues and cancer cell-line models. ATP5MGP3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ATP5MGP3 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, ATP5MGP3 RNA expression shows 6,101 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, and STAD as cancer lineages where ATP5MGP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5MGP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5MGP3 survival associations across molecular data types. ATP5MGP3 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5MGP3 RNA expression–survival associations across cancer types. High ATP5MGP3 expression shows unfavorable associations in KIRC, ACC and LIHC, but favorable associations in COAD, HNSC and LUAD. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ATP5MGP3 RNA expression.
This table summarizes ATP5MGP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5MGP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5MGP3 shows lower tumor expression in KIRC and higher tumor expression in COAD, KICH, PRAD and KIRC. The COAD box plot shows higher ATP5MGP3 RNA expression in tumor versus normal tissue (log2 FC = +0.670, t-test p < 0.001).
This table shows molecular features associated with ATP5MGP3 in patient tissues and cancer cell lines. In patient samples, ATP5MGP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
